(8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenylpropanoate
本藥之作用機轉為抑制由節後膽素激性神經所支配的平滑肌和腺體，同時對中樞神經系統還有興奮或抑制作用，依使用之劑量而定。
一般成人劑量
抗蕈毒鹼劑：肌肉、靜脈或皮下注射，400～600mcg，每4～6小時一次。
抗心律不整劑：靜脈注射，400mcg(0.4mg)~1.0mg，視需要每1～2小時一次，必要時可提高劑量至最大量2.0mg。
胃腸道低張性放射線照相：肌肉注射，1.0mg。
麻醉前給藥：肌肉注射，200～600mcg(0.2~0.6mg)，手術前1/2～1小時給藥。
解毒劑（有機磷殺蟲劑）：肌肉或靜脈注射，1.0～2.0mg，每20～30分鐘反覆給藥直到發疳消失，繼續給藥直到確切改善，有時需2天或更久。
解毒劑（蕈毒茹之蕈毒鹼）：肌肉或靜脈注射。1.0～2.0mg，每小時一次，直到呼吸效應產生。
1.AMBENONIUM
Concurrent use of AMBENONIUM and ATROPINE may result in suppression of symptoms of ambenonium overdose.
2.POTASSIUM
Concurrent use of ATROPINE and POTASSIUM may result in risk of gastrointestinal lesions
3.OXYMORPHONE
Concurrent use of OXYMORPHONE and SELECT ANTICHOLINERGICS may result in increased risk of paralytic ileus; increased risk of respiratory and CNS depression.
4.MORPHINE
Concurrent use of MORPHINE and SELECT ANTICHOLINERGICS may result in increased risk of paralytic ileus.
5.UMECLIDINIUM
Concurrent use of UMECLIDINIUM and ANTICHOLINERGICS may result in increased risk of anticholinergic adverse effects.
6.DONEPEZIL
Concurrent use of DONEPEZIL and SELECTED SEIZURE LOWERING AGENTS may result in lower seizure threshold.
7.BUPROPION
Concurrent use of BUPROPION and AGENTS LOWERING SEIZURE THRESHOLD may result in lower seizure threshold.
